EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care

Carsten Bokemeyer iD, Keith R Abrams iD, Jesus Garcia-Foncillas iD, Antoine Italiano iD, Ulrik Lassen iD, Louise Linsell iD, Marisca Marian iD, Noman Paracha iD, Sean D Sullivan, Nicoletta Brega iD, Juliette Thompson iD

JCO Precision Oncology · 2025

DOI: 10.1200/po-25-00159 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Carsten Bokemeyer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Oncology and Hematology Department, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Pyrazoles, Pyrimidines, Neoplasms, Standard of Care. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Widespread adoption of the tropomyosin receptor kinase (TRK) inhibitor larotrectinib has been hampered by limited comparisons against non–TRK inhibitor standard of care (SoC) regimens because of the rarity of TRK fusions. Cross-trial comparisons may be facilitated using matching-adjusted indirect comparison (MAIC), a validated methodology that balances baseline population characteristics. MATERIALS AND METHODS MAIC was conducted using individual patient-level data from three larotrectinib trials, compared with aggregate real-world data (RWD) from adult patients with locally advanced/metastatic TRK fusion–positive cancer in the Hartwig Medical Foundation database. Patient populations were matched on available clinical characteristics. Estimates of overall survival (OS; defined as the time from start of first postbiopsy treatment [or larotrectinib] to death) were compared between larotrectinib and non–TRK inhibitor SoC. RESULTS The analysis included 24 patients receiving nontargeted TRK inhibitor SoC and 120 receiving larotrectinib. After matching, median OS was 50.3 months (IQR, 23.3-not estimable) for larotrectinib versus 13 months (IQR, 6.4-18.3) for SoC; larotrectinib was associated with an 84% risk reduction of death (adjusted hazard ratio, 0.16 [95% CI, 0.07 to 0.36]). To account for the longer follow-up time in the larotrectinib group than in the SoC group (median: 56.7 v 23.2 months), a restricted mean survival analysis was conducted up to 26.2 months (largest observed event time in SoC arm), which showed median survival of 22.6 months for larotrectinib and 12.8 months for SoC (mean difference: 9.8 months [95% CI, 5.6 to 14.0]). CONCLUSION In patients with TRK fusion–positive cancer, larotrectinib was associated with a mean survival advantage of 9.8 months compared with non–TRK inhibitor SoC, corroborating favorable findings for larotrectinib from a previous analysis that used a different set of RWD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazolesPyrimidinesNeoplasmsStandard of CareProtein Kinase InhibitorsAntineoplastic AgentsHumansMaleFemaleMiddle AgedAgedAdult

Substanzen

larotrectinibPyrazolesPyrimidinesProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Oncology and Hematology Department, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Visible Analytics Limited, Oxford, United Kingdom.
  • Autonomous University, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain.
  • Early Phase Trials Unit, Institute Bergonié-Centre Régional de Lutte Contre le Cancer (CLCC), Bordeaux, France.
  • Oncology Department, Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark.
  • Global Oncology Division, Bayer Pharmaceuticals, Basel, Switzerland.

ORCID-Profile: Carsten Bokemeyer, Keith R Abrams, Jesus Garcia-Foncillas, Antoine Italiano, Ulrik Lassen, Louise Linsell, Marisca Marian, Noman Paracha, Nicoletta Brega, Juliette Thompson

Zitieren

APA

Bokemeyer, C., Abrams, K. R., Garcia-Foncillas, J., Italiano, A., Lassen, U., Linsell, L., Marian, M., Paracha, N., Sullivan, S. D., Brega, N., & Thompson, J. (2025). Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care. JCO Precision Oncology. https://doi.org/10.1200/po-25-00159

Vancouver

Bokemeyer C, Abrams KR, Garcia-Foncillas J, Italiano A, Lassen U, Linsell L, et al. Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care. JCO Precision Oncology. 2025. doi:10.1200/po-25-00159

BibTeX
@article{Bokemeyer2025,
  author = {Bokemeyer, Carsten and Abrams, Keith R and Garcia-Foncillas, Jesus and Italiano, Antoine and Lassen, Ulrik and Linsell, Louise and Marian, Marisca and Paracha, Noman and Sullivan, Sean D and Brega, Nicoletta and Thompson, Juliette},
  title = {Clinical Benefit From Molecularly Guided Cancer Care: A Matching-Adjusted Indirect Comparison of Larotrectinib Versus Standard of Care},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-25-00159}
}
Kostenlos starten →